Ochsner Cancer Institute: Mesothelioma Care in the Gulf South

Imagine you've spent three decades working in the petrochemical refineries along the Mississippi River corridor, a stretch of Louisiana industry sometimes called "Cancer Alley." You've just received a diagnosis of pleural mesothelioma, and your oncologist tells you that Ochsner Cancer Institute, less than an hour away in New Orleans, has a dedicated team that handles exactly this disease. That scenario plays out more often in Louisiana than almost anywhere else in the country, and it's precisely why Ochsner's mesothelioma program matters to patients across the Gulf South.

Ochsner Cancer Institute, the oncology division of Ochsner Health, is the largest not-for-profit academic health system in Louisiana. Its main campus sits on Jefferson Highway in New Orleans, with satellite cancer care locations in Baton Rouge, Covington, and Mandeville. According to Ochsner Health's own institutional reporting, the cancer institute treats more than 5,000 newly diagnosed cancer patients each year, and thoracic malignancies, including malignant mesothelioma, represent a meaningful subset of that volume given the region's industrial history.

Mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. According to the National Cancer Institute (NCI), approximately 3,000 new cases are diagnosed in the United States annually. Louisiana's shipbuilding heritage, offshore oil industry, and dense network of chemical plants have left generations of workers at elevated risk. The Ochsner Cancer Institute sits at the intersection of that occupational history and modern oncologic care, offering patients access to surgical expertise, systemic therapy, and emerging clinical research without requiring travel to distant academic centers.

"For patients in this region, distance to specialized care has historically been a real barrier," reflects the perspective embedded in Ochsner's community health mission. "Having a program that understands the local exposure history, the industries, and the communities makes a clinical difference." The institute's multidisciplinary model means that a newly diagnosed mesothelioma patient doesn't navigate specialists one by one. Instead, surgeons, medical oncologists, radiation oncologists, pulmonologists, and palliative care specialists review each case together, typically through a formal tumor board conference.

Ochsner Cancer Institute evaluates and treats all recognized histologic subtypes of mesothelioma, and the distinction between subtypes is clinically critical because it shapes every treatment decision a patient will face. According to the NCI, the three primary subtypes are epithelioid, sarcomatoid, and biphasic (mixed) mesothelioma. Epithelioid is the most common, accounting for roughly 50 to 70 percent of cases, and it carries the most favorable prognosis among the three.

By site of origin, mesothelioma is further classified as pleural (arising from the lining of the lungs), peritoneal (arising from the abdominal lining), pericardial (arising from the heart sac), or tunica vaginalis (arising from the lining of the testes). Pleural mesothelioma represents roughly 75 to 80 percent of all cases, according to the American Cancer Society. Ochsner's thoracic surgery and surgical oncology teams are equipped to evaluate patients with both pleural and peritoneal disease, with peritoneal cases potentially considered for hyperthermic intraperitoneal chemotherapy (HIPEC), a procedure that requires specialized surgical training and infrastructure.

Diagnosis at Ochsner Cancer Institute begins, as it does at most major centers, with imaging. A patient presenting with unexplained pleural effusion (fluid around the lungs), chest pain, or progressive shortness of breath will typically undergo a computed tomography (CT) scan of the chest and abdomen. According to the American College of Radiology, CT imaging is the standard first-line modality for evaluating suspected pleural disease. If imaging raises concern for mesothelioma, the next step is tissue confirmation, because no blood test or scan alone can definitively diagnose this cancer.

Tissue biopsy is the diagnostic cornerstone. Ochsner's interventional pulmonology and thoracic surgery teams perform several biopsy approaches depending on the clinical picture. Thoracentesis (fluid sampling) is the least invasive but carries a lower diagnostic yield for mesothelioma compared to solid tissue biopsy. Video-assisted thoracoscopic surgery (VATS) pleuroscopy, which allows direct visualization of the pleural surface, provides larger tissue samples and is considered the gold standard for pleural mesothelioma diagnosis. According to a 2018 review published in the Journal of Thoracic Disease, VATS-guided biopsy achieves diagnostic accuracy exceeding 95 percent in experienced hands.

Pathologic analysis at Ochsner includes immunohistochemical staining panels to distinguish mesothelioma from adenocarcinoma and other pleural tumors that can mimic it radiographically. Markers such as calretinin, WT-1, D2-40, and CK5/6 are routinely used, as recommended in guidelines from the College of American Pathologists. Molecular profiling, including assessment of BAP1 loss and CDKN2A (p16) deletion by fluorescence in situ hybridization (FISH), can further support the diagnosis and provide prognostic information. Once pathology is confirmed, formal staging using the current IASLC/IMIG staging system guides treatment planning discussions at the multidisciplinary tumor board.

Consider a 62-year-old former shipyard welder from the Avondale Shipyards, a facility west of New Orleans that the U.S. Department of Justice identified as a major site of asbestos use. He presents to Ochsner with stage II epithelioid pleural mesothelioma. His case goes before the tumor board within days of diagnosis. That board, which may include six or more specialists, will debate whether he is a surgical candidate, which chemotherapy backbone to use, and whether any open clinical trials match his molecular profile. That deliberate, team-based approach is the defining feature of mesothelioma care at centers like Ochsner.

Surgical options for eligible patients at Ochsner include pleurectomy/decortication (P/D) and the more extensive extrapleural pneumonectomy (EPP). According to a landmark 2011 study published in the Journal of Clinical Oncology by Flores and colleagues, P/D has increasingly been favored over EPP at many centers because it preserves lung function while achieving comparable local control in appropriately selected patients. The choice between procedures depends on tumor extent, histology, and the patient's cardiopulmonary reserve.

First-line systemic therapy for mesothelioma changed significantly in 2020 when the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for unresectable pleural mesothelioma, based on the CheckMate 743 trial published in The Lancet in 2021. Prior to that approval, pemetrexed (Alimta) plus cisplatin or carboplatin had been the standard first-line regimen since FDA approval in 2004. Ochsner's medical oncologists are experienced with both immunotherapy combinations and cytotoxic chemotherapy regimens, tailoring the choice to each patient's disease stage, histology, and performance status.

Radiation therapy plays a supporting role in mesothelioma management, primarily for symptom palliation or as part of multimodality protocols following surgery. Ochsner's radiation oncology department uses intensity-modulated radiation therapy (IMRT) and image-guided techniques to deliver precise doses to the pleural surface while limiting exposure to adjacent heart and lung tissue. The institute also connects eligible patients to clinical trials through its participation in NCI-supported cooperative oncology groups, giving patients access to investigational agents that may not yet be widely available.

Mesothelioma prognosis remains challenging regardless of where a patient is treated, and honest communication about this reality is a cornerstone of quality cancer care. According to the NCI's SEER database, the median survival for pleural mesothelioma across all stages is approximately 12 months from diagnosis, though this figure reflects historical data that predates the 2020 immunotherapy approval and ongoing advances in multimodality care. Patients with early-stage epithelioid disease who undergo aggressive surgical resection combined with chemotherapy have reported median survivals of 20 to 30 months in specialized center series.

Prognostic factors that Ochsner's team evaluates include histologic subtype (epithelioid carries the best prognosis), clinical stage at diagnosis, patient performance status, platelet count, and presence or absence of BAP1 mutation. A 2019 analysis published in JAMA Oncology identified BAP1 germline mutations as associated with a more favorable prognosis and a distinct hereditary mesothelioma syndrome, making genetic counseling a relevant consideration for some patients. Ochsner's cancer genetics program can facilitate this evaluation when clinically appropriate.

Palliative care is integrated into mesothelioma treatment at Ochsner from the time of diagnosis, not just at end of life. Research published in the New England Journal of Medicine in 2010 by Temel and colleagues demonstrated that early palliative care integration improved quality of life and, notably, survival in patients with thoracic malignancies. Ochsner's palliative care team addresses pain, dyspnea, fatigue, and psychological distress in parallel with active cancer treatment.

A mesothelioma diagnosis reshapes daily life in ways that extend well beyond clinic appointments. Patients treated at Ochsner Cancer Institute have access to a range of supportive services designed to address the full scope of that disruption. The institute's social work team can connect patients with financial assistance programs, transportation resources, and community support organizations. Louisiana residents may also be eligible for state-specific assistance programs given the recognized occupational exposure history in the region.

Nutrition counseling is available through Ochsner's oncology dietitian staff, and it's particularly relevant for mesothelioma patients, who frequently experience weight loss and muscle wasting (cancer cachexia) as the disease progresses. Respiratory therapy and pulmonary rehabilitation can help patients manage breathlessness following pleural procedures or surgical resection. The Mesothelioma Applied Research Foundation (MARF) and the Asbestos Disease Awareness Organization (ADAO) both maintain patient support resources and peer connection programs that complement clinical care.

Many mesothelioma patients and their families also pursue legal consultation, given that the disease is almost always attributable to preventable asbestos exposure. Ochsner's social work team can provide referrals to patient advocacy organizations that connect individuals with legal resources, though the institute itself does not provide legal advice. Understanding your legal options is a separate but important part of navigating a mesothelioma diagnosis, and many asbestos trust funds have specific filing deadlines tied to state statutes of limitations.